Ketanserin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in hypertension and peripheral vascular disease
- PMID: 2079001
- DOI: 10.2165/00003495-199040060-00010
Ketanserin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in hypertension and peripheral vascular disease
Abstract
Ketanserin is a 5-HT2 receptor antagonist without partial agonist properties which also possesses weak alpha 1-adrenoceptor antagonistic activity, which may explain its antihypertensive mechanism of action in patients with essential hypertension. It also inhibits the effects of serotonin on platelets in cardiovascular disease, inhibits vasoconstriction caused by the amine, and when administered intravenously improves some haemorheological indices in patients with ischaemic diseases. The antihypertensive effect of oral ketanserin 40 mg twice daily is comparable with that of total daily doses of metoprolol 200 mg, propranolol 160 mg, captopril 100 mg, enalapril 20 mg, hydrochlorothiazide 50 mg, or alpha-methyldopa 1000 mg and is achieved without adverse effect on plasma lipoproteins or carbohydrate metabolism in patients with concomitant diabetes mellitus. Evidence from prospective studies suggests a greater antihypertensive efficacy in the elderly than in younger patients. In patients with intermittent claudication, results have been inconsistent in small studies, while a large study showed no improvement in pain-free walking distance but fewer amputations compared to placebo. In Raynaud's phenomenon symptomatic improvement relative to placebo was achieved in larger trials. Its role in preventing atherosclerotic complications requires further investigation. Ketanserin is reasonably well tolerated, the frequency of adverse effects being comparable with that of other antihypertensive drugs in controlled trials. Dizziness, tiredness, oedema, dry mouth and weight gain are the most commonly reported effects. Ketanserin prolongs QT interval in a dose-related manner, and when given in certain predisposing circumstances ventricular arrhythmias and syncope may occur. Administered intravenously, ketanserin 10mg followed by an infusion of 2 to 4 mg/h controls moderate to severe pre- and postoperative hypertension in most patients, acting as a balanced vasodilator, lowering cardiac pre- and afterload. Although the arrhythmogenic potential of ketanserin in patients receiving potassium-depleting diuretics requires suitable precautions, it appears that its antihypertensive activity is suited to the elderly provided plasma potassium concentrations are normal at the start of treatment and are maintained within the normal range.
Similar articles
-
[Blockade of 5-HT2 receptors as a mechanism of antihypertensive action of ketanserin].Srp Arh Celok Lek. 1994 Mar-Apr;122(3-4):99-102. Srp Arh Celok Lek. 1994. PMID: 17972821 Review. Serbian.
-
Ageing, serotonin and ketanserin.Drugs. 1988;36 Suppl 1:44-54. doi: 10.2165/00003495-198800361-00008. Drugs. 1988. PMID: 3071462 Review.
-
Serotoninergic mechanisms in hypertension. Focus on the effects of ketanserin.Hypertension. 1988 Feb;11(2):111-33. doi: 10.1161/01.hyp.11.2.111. Hypertension. 1988. PMID: 3277910 Review.
-
Effects of a new serotonin antagonist, ketanserin, in experimental and clinical hypertension.Am J Hypertens. 1988 Jul;1(3 Pt 3):317S-323S. doi: 10.1093/ajh/1.3.317s. Am J Hypertens. 1988. PMID: 3046635 Review.
-
Clinical aspects during therapy with the serotonin antagonist ketanserin.Clin Physiol Biochem. 1990;8 Suppl 3:64-80. Clin Physiol Biochem. 1990. PMID: 1983424 Review.
Cited by
-
Inhibition of Rac1-dependent forgetting alleviates memory deficits in animal models of Alzheimer's disease.Protein Cell. 2019 Oct;10(10):745-759. doi: 10.1007/s13238-019-0641-0. Epub 2019 Jul 18. Protein Cell. 2019. PMID: 31321704 Free PMC article.
-
Role of serotonin in the pathogenesis of acute and chronic pulmonary hypertension.Thorax. 1999 Feb;54(2):161-8. doi: 10.1136/thx.54.2.161. Thorax. 1999. PMID: 10325923 Free PMC article. Review. No abstract available.
-
The Effects of Four Compounds That Act on the Dopaminergic and Serotonergic Systems on Working Memory in Animal Studies; A Literature Review.Brain Sci. 2023 Mar 25;13(4):546. doi: 10.3390/brainsci13040546. Brain Sci. 2023. PMID: 37190512 Free PMC article. Review.
-
Clozapine impaired glucose-stimulated insulin secretion partly by increasing plasma 5-HT levels due to the inhibition of OCT1-mediated hepatic 5-HT uptake in mice.Acta Pharmacol Sin. 2025 Mar;46(3):687-701. doi: 10.1038/s41401-024-01401-w. Epub 2024 Oct 29. Acta Pharmacol Sin. 2025. PMID: 39472495
-
Ligand-Dependent Conformational Transitions in Molecular Dynamics Trajectories of GPCRs Revealed by a New Machine Learning Rare Event Detection Protocol.Molecules. 2021 May 20;26(10):3059. doi: 10.3390/molecules26103059. Molecules. 2021. PMID: 34065494 Free PMC article.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical